Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8790497 | American Journal of Ophthalmology | 2018 | 27 Pages |
Abstract
Despite the growing preference for the T&E regimen, there is limited head-to-head evidence comparing dosing strategies. The evidence available, however, suggests that at 12Â months, T&E is comparable to monthly and superior to PRN dosing for both efficacy and safety outcomes when using ranibizumab.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Mali Okada, Rathika Kandasamy, Elaine W. Chong, Myra McGuiness, Robyn H. Guymer,